Clinical Trials
3
Active:0
Completed:2
Trial Phases
3 Phases
Phase 2:1
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (33.3%)Phase 2
1 (33.3%)Phase 4
1 (33.3%)Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
Phase 4
Terminated
- Conditions
- Neovascular Age-related Macular DegenerationRetinal Vein OcclusionDiabetic Macular Edema
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 10
- Registration Number
- NCT04563299
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Not Applicable
Completed
- Conditions
- Age-related Macular DegenerationCentral Retinal Vein OcclusionDiabetic Macular Edema
- Interventions
- Procedure: Xylocaine 2% Injectable AnestheticDrug: Tetravisc 0.5% GelDrug: Intra-vitreal Anti-VEGF Drug
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 57
- Registration Number
- NCT01640171
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Clearwater, Florida, United States
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Retina Vitreous Associates of Florida
- Target Recruit Count
- 20
- Registration Number
- NCT01476449
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
News
No news found